Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 08:58
06/05/20
06/05
08:58
06/05/20
08:58
ACTG

Acacia Research

$3.19 /

+0.22 (+7.41%)

, OXFD

Oxford Immunotec

$12.95 /

-0.18 (-1.37%)

, KNDI

Kandi Technologies

$3.55 /

+0.13 (+3.80%)

, AVGO

Broadcom

$309.06 /

-0.49 (-0.16%)

, DOMO

Domo

$28.99 /

-2.16 (-6.93%)

, WORK

Slack Technologies

$37.90 /

-1.98 (-4.96%)

, GPS

Gap

$12.14 /

+0.195 (+1.63%)

, YEXT

Yext

$16.63 /

-1.02 (-5.78%)

, MNLO

Menlo Therapeutics

$2.21 /

+0.085 (+4.01%)

, GME

GameStop

$4.45 /

+ (+0.00%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
YEXT Yext
$16.63 /

-1.02 (-5.78%)

WORK Slack Technologies
$37.90 /

-1.98 (-4.96%)

OXFD Oxford Immunotec
$12.95 /

-0.18 (-1.37%)

MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

KNDI Kandi Technologies
$3.55 /

+0.13 (+3.80%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

GME GameStop
$4.45 /

+ (+0.00%)

DOMO Domo
$28.99 /

-2.16 (-6.93%)

AVGO Broadcom
$309.06 /

-0.49 (-0.16%)

ACTG Acacia Research
$3.19 /

+0.22 (+7.41%)

ACTG Acacia Research
$3.19 /

+0.22 (+7.41%)

05/22/20 Craig-Hallum
Acacia Research initiated with a Buy at Craig-Hallum
OXFD Oxford Immunotec
$12.95 /

-0.18 (-1.37%)

09/24/19 Cowen
Oxford Immunotec company sale may make sense, says Cowen
09/18/19 Piper Sandler
Oxford Immunotec's new approach to China could boost sales, says Piper Jaffray
KNDI Kandi Technologies
$3.55 /

+0.13 (+3.80%)

AVGO Broadcom
$309.06 /

-0.49 (-0.16%)

06/05/20 Loop Capital
Broadcom price target raised to $345 from $260 at Loop Capital
06/05/20 KeyBanc
Broadcom price target raised to $360 from $290 at KeyBanc
06/05/20 Deutsche Bank
Broadcom price target raised to $360 from $300 at Deutsche Bank
06/05/20 Rosenblatt
Broadcom price target raised to $370 from $350 at Rosenblatt
DOMO Domo
$28.99 /

-2.16 (-6.93%)

06/05/20 Needham
Domo price target raised to $38 from $28 at Needham
06/05/20 JMP Securities
Domo price target raised to $35 from $22 at JMP Securities
04/13/20 Needham
Domo price target lowered to $25 from $31 at Needham
03/19/20 William Blair
William Blair constructive on Domo's incremental model visibility amid pandemic
WORK Slack Technologies
$37.90 /

-1.98 (-4.96%)

06/05/20 Monness Crespi
Monness Crespi downgrades Slack to Neutral on 'less compelling' valuation
06/05/20 Cowen
Slack Technologies weakness a buying opportunity, says Cowen
06/05/20 Monness Crespi
Slack Technologies downgraded to Neutral from Buy at Monness Crespi
06/05/20 Cantor Fitzgerald
Slack Technologies price target raised to $38 from $30 at Cantor Fitzgerald
GPS Gap
$12.14 /

+0.195 (+1.63%)

06/05/20 RBC Capital
Gap price target raised to $13 from $8 at RBC Capital
06/05/20 Citi
Gap price target raised to $12 from $10 at Citi
06/01/20
Fly Intel: Top five analyst upgrades
06/01/20 JPMorgan
Gap upgraded to Neutral from Underweight on valuation at JPMorgan
YEXT Yext
$16.63 /

-1.02 (-5.78%)

12/06/19 DA Davidson
Yext price target lowered to $16.50 from $24 at DA Davidson
12/06/19 RBC Capital
Yext price target lowered to $20 from $24 at RBC Capital
12/06/19 JPMorgan
Yext price target lowered to $16 from $20 at JPMorgan
12/06/19 Oppenheimer
Yext price target lowered to $21 from $26 at Oppenheimer
MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

06/01/20 Northland
Menlo Therapeutics price target raised to $6 from $3.50 at Northland
06/01/20 H.C. Wainwright
Menlo Therapeutics price target raised to $3.50 from $2.50 at H.C. Wainwright
05/29/20 Cantor Fitzgerald
Menlo set up for 'successful' Q4 launch of Zilxi, says Cantor Fitzgerald
05/21/20 Northland
Menlo Therapeutics initiated with an Outperform at Northland
GME GameStop
$4.45 /

+ (+0.00%)

04/21/20 Baird
GameStop FY20 EPS target cut at Baird
03/27/20 Baird
GameStop trneds to remain weak despite recent increase, says Baird
03/20/20
Fly Intel: Top five analyst downgrades
03/20/20 Benchmark
GameStop does not qualify as an essential retailer, says Benchmark
YEXT Yext
$16.63 /

-1.02 (-5.78%)

WORK Slack Technologies
$37.90 /

-1.98 (-4.96%)

OXFD Oxford Immunotec
$12.95 /

-0.18 (-1.37%)

MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

KNDI Kandi Technologies
$3.55 /

+0.13 (+3.80%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

GME GameStop
$4.45 /

+ (+0.00%)

DOMO Domo
$28.99 /

-2.16 (-6.93%)

AVGO Broadcom
$309.06 /

-0.49 (-0.16%)

  • 05
    Jun
WORK Slack Technologies
$37.90 /

-1.98 (-4.96%)

OXFD Oxford Immunotec
$12.95 /

-0.18 (-1.37%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

GME GameStop
$4.45 /

+ (+0.00%)

DOMO Domo
$28.99 /

-2.16 (-6.93%)

AVGO Broadcom
$309.06 /

-0.49 (-0.16%)

ACTG Acacia Research
$3.19 /

+0.22 (+7.41%)

YEXT Yext
$16.63 /

-1.02 (-5.78%)

WORK Slack Technologies
$37.90 /

-1.98 (-4.96%)

MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

GME GameStop
$4.45 /

+ (+0.00%)

DOMO Domo
$28.99 /

-2.16 (-6.93%)

AVGO Broadcom
$309.06 /

-0.49 (-0.16%)

WORK Slack Technologies
$37.90 /

-1.98 (-4.96%)

MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

GME GameStop
$4.45 /

+ (+0.00%)

AVGO Broadcom
$309.06 /

-0.49 (-0.16%)

Syndicate
Menlo Therapeutics 27.1M share Spot Secondary priced at $1.85 » 07:12
06/05/20
06/05
07:12
06/05/20
07:12
MNLO

Menlo Therapeutics

$2.21 /

+0.085 (+4.01%)

Cowen and Piper Sandler…

Cowen and Piper Sandler acted as joint book running managers for the offering.

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

06/01/20 Northland
Menlo Therapeutics price target raised to $6 from $3.50 at Northland
06/01/20 H.C. Wainwright
Menlo Therapeutics price target raised to $3.50 from $2.50 at H.C. Wainwright
05/29/20 Cantor Fitzgerald
Menlo set up for 'successful' Q4 launch of Zilxi, says Cantor Fitzgerald
05/21/20 Northland
Menlo Therapeutics initiated with an Outperform at Northland
MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

  • 05
    Jun
MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

On The Fly
Fly Intel: After-Hours Movers » 19:05
06/04/20
06/04
19:05
06/04/20
19:05
DOMO

Domo

$28.99 /

-2.16 (-6.93%)

, MTN

Vail Resorts

$207.83 /

+5.99 (+2.97%)

, DOCU

DocuSign

$139.98 /

-7.48 (-5.07%)

, RH

RH

$248.55 /

-6.32 (-2.48%)

, AVGO

Broadcom

$309.06 /

-0.49 (-0.16%)

, IMUX

Immunic

$11.30 /

-0.75 (-6.22%)

, VECO

Veeco

$12.68 /

+0.37 (+3.01%)

, WORK

Slack Technologies

$37.90 /

-1.98 (-4.96%)

, GPS

Gap

$12.14 /

+0.195 (+1.63%)

, YEXT

Yext

$16.63 /

-1.02 (-5.78%)

, COO

Cooper Companies

$313.58 /

-5.64 (-1.77%)

, PD

PagerDuty

$27.05 /

-1.27 (-4.48%)

, CAL

Caleres

$9.53 /

+0.97 (+11.33%)

, MDB

MongoDB

$220.66 /

-13.25 (-5.66%)

, ZUMZ

Zumiez

$29.25 /

+1.51 (+5.44%)

, MNLO

Menlo Therapeutics

$2.21 /

+0.085 (+4.01%)

, GME

GameStop

$4.45 /

+ (+0.00%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
ZUMZ Zumiez
$29.25 /

+1.51 (+5.44%)

YEXT Yext
$16.63 /

-1.02 (-5.78%)

WORK Slack Technologies
$37.90 /

-1.98 (-4.96%)

VECO Veeco
$12.68 /

+0.37 (+3.01%)

RH RH
$248.55 /

-6.32 (-2.48%)

PD PagerDuty
$27.05 /

-1.27 (-4.48%)

MTN Vail Resorts
$207.83 /

+5.99 (+2.97%)

MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

MDB MongoDB
$220.66 /

-13.25 (-5.66%)

IMUX Immunic
$11.30 /

-0.75 (-6.22%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

GME GameStop
$4.45 /

+ (+0.00%)

DOMO Domo
$28.99 /

-2.16 (-6.93%)

DOCU DocuSign
$139.98 /

-7.48 (-5.07%)

COO Cooper Companies
$313.58 /

-5.64 (-1.77%)

CAL Caleres
$9.53 /

+0.97 (+11.33%)

AVGO Broadcom
$309.06 /

-0.49 (-0.16%)

DOMO Domo
$28.99 /

-2.16 (-6.93%)

04/13/20 Needham
Domo price target lowered to $25 from $31 at Needham
03/19/20 William Blair
William Blair constructive on Domo's incremental model visibility amid pandemic
03/19/20 JMP Securities
Domo price target lowered to $25 from $35 at JMP Securities
03/11/20 Cowen
Domo price target lowered to $28 from $35 at Cowen
MTN Vail Resorts
$207.83 /

+5.99 (+2.97%)

06/01/20
Fly Intel: Top five analyst downgrades
06/01/20 Deutsche Bank
Vail Resorts downgraded to Hold on valuation at Deutsche Bank
05/31/20 Deutsche Bank
Vail Resorts downgraded to Hold from Buy at Deutsche Bank
05/21/20 Credit Suisse
Vail Resorts initiated with an Outperform at Credit Suisse
DOCU DocuSign
$139.98 /

-7.48 (-5.07%)

06/04/20 JMP Securities
DocuSign price target raised to $150 from $113 at JMP Securities
05/28/20 Wedbush
DocuSign price target raised to $140 from $115 at Wedbush
05/21/20 RBC Capital
DocuSign price target raised to $150 from $85 at RBC Capital
05/21/20 Citi
DocuSign price target raised to $150 from $85 at Citi
RH RH
$248.55 /

-6.32 (-2.48%)

06/03/20 Wells Fargo
RH price target raised to $275 from $130 at Wells Fargo
06/03/20 Wedbush
RH price target raised to $270 from $150 at Wedbush
06/02/20 Stifel
RH price target raised to $265 from $150 at Stifel
06/02/20
Fly Intel: Top five analyst upgrades
AVGO Broadcom
$309.06 /

-0.49 (-0.16%)

06/02/20 JPMorgan
Broadcom shares have additional 20%-30% upside, says JPMorgan
06/02/20 Susquehanna
Broadcom price target raised to $340 from $300 at Susquehanna
05/08/20 DA Davidson
SailPoint price target raised to $24 from $18 at DA Davidson
05/04/20 KeyBanc
Apple cautious iPhone outlook likely a headwind for chip suppliers, says KeyBanc
IMUX Immunic
$11.30 /

-0.75 (-6.22%)

06/04/20 Wedbush
Wedbush starts Immunic at Outperform with $59 price target
06/04/20 Wedbush
Immunic initiated with an Outperform at Wedbush
05/11/20
Fly Intel: Top five analyst initiations
05/11/20 H.C. Wainwright
Immunic initiated with a Buy, $45 price target at H.C. Wainwright
VECO Veeco
$12.68 /

+0.37 (+3.01%)

06/04/20 Oppenheimer
Veeco initiated with an Outperform at Oppenheimer
03/03/20 Stifel
Veeco upgraded to Buy from Hold at Stifel
WORK Slack Technologies
$37.90 /

-1.98 (-4.96%)

06/02/20
Fly Intel: Top five analyst initiations
06/02/20 Cowen
Cowen starts Slack with Outperform given 'major booster shot' from COVID
06/02/20 Cowen
Slack Technologies initiated with an Outperform at Cowen
05/29/20 Stephens
Slack Technologies price target raised to $37 from $32 at Stephens
GPS Gap
$12.14 /

+0.195 (+1.63%)

06/01/20
Fly Intel: Top five analyst upgrades
06/01/20 JPMorgan
Gap upgraded to Neutral from Underweight on valuation at JPMorgan
06/01/20 JPMorgan
Gap upgraded to Neutral from Underweight at JPMorgan
04/27/20 Barclays
Gap price target lowered to $5 from $10 at Barclays
YEXT Yext
$16.63 /

-1.02 (-5.78%)

12/06/19 DA Davidson
Yext price target lowered to $16.50 from $24 at DA Davidson
12/06/19 RBC Capital
Yext price target lowered to $20 from $24 at RBC Capital
12/06/19 JPMorgan
Yext price target lowered to $16 from $20 at JPMorgan
12/06/19 Oppenheimer
Yext price target lowered to $21 from $26 at Oppenheimer
COO Cooper Companies
$313.58 /

-5.64 (-1.77%)

05/26/20 Stephens
Cooper Companies price target raised to $325 from $300 at Stephens
05/26/20 KeyBanc
Cooper Companies price target lowered to $330 from $380 at KeyBanc
05/21/20 Wells Fargo
Cooper Companies price target lowered to $329 from $388 at Wells Fargo
04/21/20 Raymond James
Cooper Companies price target lowered to $340 from $360 at Raymond James
PD PagerDuty
$27.05 /

-1.27 (-4.48%)

05/28/20 RBC Capital
PagerDuty price target raised to $30 from $22 at RBC Capital
03/19/20 RBC Capital
PagerDuty price target lowered to $22 from $30 at RBC Capital
12/06/19 SunTrust
PagerDuty price target lowered to $25 from $32 at SunTrust
12/06/19 DA Davidson
PagerDuty price target lowered to $24 from $36 at DA Davidson
CAL Caleres
$9.53 /

+0.97 (+11.33%)

03/13/20 Susquehanna
Caleres downgraded to Neutral from Positive at Susquehanna
02/18/20 Susquehanna
Caleres price target lowered to $17 from $25 at Susquehanna
02/18/20 Wedbush
Caleres price target lowered to $20 from $27 at Wedbush
01/29/20 Needham
Caleres downgraded to Hold from Buy at Needham
MDB MongoDB
$220.66 /

-13.25 (-5.66%)

06/02/20 Barclays
MongoDB price target raised to $275 from $130 at Barclays
05/22/20 Stifel
MongoDB price target raised to $225 from $160 at Stifel
04/19/20 Stifel
MongoDB price target raised to $160 from $135 at Stifel
03/18/20 Oppenheimer
MongoDB price target lowered to $140 from $155 at Oppenheimer
ZUMZ Zumiez
$29.25 /

+1.51 (+5.44%)

06/04/20 Wedbush
Zumiez price target raised to $28 from $20 at Wedbush
03/16/20 DA Davidson
Zumiez price target lowered to $20 from $33 at DA Davidson
03/13/20 Pivotal Research
Zumiez price target lowered to $21 from $26 at Pivotal Research
03/11/20 Wedbush
Zumiez upgraded to Neutral at Wedbush as recent selloff resets valuation
MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

06/01/20 Northland
Menlo Therapeutics price target raised to $6 from $3.50 at Northland
06/01/20 H.C. Wainwright
Menlo Therapeutics price target raised to $3.50 from $2.50 at H.C. Wainwright
05/29/20 Cantor Fitzgerald
Menlo set up for 'successful' Q4 launch of Zilxi, says Cantor Fitzgerald
05/21/20 Northland
Menlo Therapeutics initiated with an Outperform at Northland
GME GameStop
$4.45 /

+ (+0.00%)

04/21/20 Baird
GameStop FY20 EPS target cut at Baird
03/27/20 Baird
GameStop trneds to remain weak despite recent increase, says Baird
03/20/20
Fly Intel: Top five analyst downgrades
03/20/20 Benchmark
GameStop does not qualify as an essential retailer, says Benchmark
ZUMZ Zumiez
$29.25 /

+1.51 (+5.44%)

YEXT Yext
$16.63 /

-1.02 (-5.78%)

WORK Slack Technologies
$37.90 /

-1.98 (-4.96%)

VECO Veeco
$12.68 /

+0.37 (+3.01%)

RH RH
$248.55 /

-6.32 (-2.48%)

PD PagerDuty
$27.05 /

-1.27 (-4.48%)

MTN Vail Resorts
$207.83 /

+5.99 (+2.97%)

MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

MDB MongoDB
$220.66 /

-13.25 (-5.66%)

IMUX Immunic
$11.30 /

-0.75 (-6.22%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

GME GameStop
$4.45 /

+ (+0.00%)

DOMO Domo
$28.99 /

-2.16 (-6.93%)

DOCU DocuSign
$139.98 /

-7.48 (-5.07%)

COO Cooper Companies
$313.58 /

-5.64 (-1.77%)

CAL Caleres
$9.53 /

+0.97 (+11.33%)

AVGO Broadcom
$309.06 /

-0.49 (-0.16%)

  • 05
    Jun
WORK Slack Technologies
$37.90 /

-1.98 (-4.96%)

RH RH
$248.55 /

-6.32 (-2.48%)

MTN Vail Resorts
$207.83 /

+5.99 (+2.97%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

GME GameStop
$4.45 /

+ (+0.00%)

DOMO Domo
$28.99 /

-2.16 (-6.93%)

AVGO Broadcom
$309.06 /

-0.49 (-0.16%)

ZUMZ Zumiez
$29.25 /

+1.51 (+5.44%)

YEXT Yext
$16.63 /

-1.02 (-5.78%)

WORK Slack Technologies
$37.90 /

-1.98 (-4.96%)

VECO Veeco
$12.68 /

+0.37 (+3.01%)

RH RH
$248.55 /

-6.32 (-2.48%)

MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

MDB MongoDB
$220.66 /

-13.25 (-5.66%)

IMUX Immunic
$11.30 /

-0.75 (-6.22%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

GME GameStop
$4.45 /

+ (+0.00%)

DOMO Domo
$28.99 /

-2.16 (-6.93%)

DOCU DocuSign
$139.98 /

-7.48 (-5.07%)

AVGO Broadcom
$309.06 /

-0.49 (-0.16%)

WORK Slack Technologies
$37.90 /

-1.98 (-4.96%)

RH RH
$248.55 /

-6.32 (-2.48%)

PD PagerDuty
$27.05 /

-1.27 (-4.48%)

MTN Vail Resorts
$207.83 /

+5.99 (+2.97%)

MNLO Menlo Therapeutics
$2.21 /

+0.085 (+4.01%)

MDB MongoDB
$220.66 /

-13.25 (-5.66%)

GPS Gap
$12.14 /

+0.195 (+1.63%)

GME GameStop
$4.45 /

+ (+0.00%)

DOCU DocuSign
$139.98 /

-7.48 (-5.07%)

AVGO Broadcom
$309.06 /

-0.49 (-0.16%)

Syndicate
Menlo Therapeutics files to sell common stock, no amount given » 16:01
06/04/20
06/04
16:01
06/04/20
16:01
MNLO

Menlo Therapeutics

$2.19 /

+0.07 (+3.30%)

Cowen and Piper Sandler…

Cowen and Piper Sandler & Co. are acting as joint book-runners for the proposed offering. LifeSci Capital LLC is acting as lead manager

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$2.19 /

+0.07 (+3.30%)

MNLO Menlo Therapeutics
$2.19 /

+0.07 (+3.30%)

06/01/20 Northland
Menlo Therapeutics price target raised to $6 from $3.50 at Northland
06/01/20 H.C. Wainwright
Menlo Therapeutics price target raised to $3.50 from $2.50 at H.C. Wainwright
05/29/20 Cantor Fitzgerald
Menlo set up for 'successful' Q4 launch of Zilxi, says Cantor Fitzgerald
05/21/20 Northland
Menlo Therapeutics initiated with an Outperform at Northland
MNLO Menlo Therapeutics
$2.19 /

+0.07 (+3.30%)

MNLO Menlo Therapeutics
$2.19 /

+0.07 (+3.30%)

MNLO Menlo Therapeutics
$2.19 /

+0.07 (+3.30%)

Hot Stocks
Menlo Therapeutics announces results from Phase 2 trial of FCD105 » 08:02
06/02/20
06/02
08:02
06/02/20
08:02
MNLO

Menlo Therapeutics

$2.37 /

-0.005 (-0.21%)

Menlo Therapeutics…

Menlo Therapeutics announced positive results from a Phase 2 clinical trial evaluating the preliminary safety and efficacy of FCD105, the first ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris. Study FX2016-40 enrolled 447 patients in the United States who were randomized to either FCD105 foam, 3% minocycline foam, 0.3% adapalene foam, or vehicle foam. The Company has begun preparations to conduct an End of Phase 2 meeting with the FDA before the end of this year. FCD105 showed a highly statistically significant improvement compared to vehicle for the endpoints of Investigator's Global Assessment treatment success and absolute change from baseline in mean inflammatory counts at Week 12. The proportion of patients achieving IGA treatment success in the FCD105 treatment group was 35.9% compared to 15.7% of patients in the vehicle treatment group. Absolute reduction in inflammatory lesion counts at Week 12 was -19.4 for the FCD105 treatment group compared to -15.58 for the vehicle treatment group. The trial was not originally powered to demonstrate a statistical difference between FCD105 and either 3% minocycline foam or 0.3% adapalene foam treatments; however, the majority of these comparisons did show a statistically significant improvement of FCD105 at Week 12. Numerical improvement was observed for FCD105 on all efficacy endpoints for these comparisons at Week 12. Absolute reduction in non-inflammatory lesion counts at Week 12 was also assessed with a mean lesion count reduction of -24.94 for the FCD105 treatment group compared to -22.87 for the vehicle treatment group. Although numerical improvement was shown, this was not statistically significant, which has been attributed to outlier results affecting both FCD105 and vehicle treatment groups. Conversely, absolute reduction in non-inflammatory lesion counts at Week 12 for FCD105 did show a statistically significant improvement compared to each of 3% minocycline foam and 0.3% adapalene foam. The most commonly reported treatment-emergent adverse event in the trial was upper respiratory tract infection with dry skin being the most commonly reported cutaneous adverse event. The majority of adverse events were assessed as mild in severity. There were no serious adverse events. FCD105 was comparably tolerated to vehicle in all local skin tolerability assessments with 93% or greater of severity scores being assessed as "none" or "mild" for burning/stinging, itching, dryness, scaling, erythema and hyperpigmentation.

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$2.37 /

-0.005 (-0.21%)

MNLO Menlo Therapeutics
$2.37 /

-0.005 (-0.21%)

06/01/20 Northland
Menlo Therapeutics price target raised to $6 from $3.50 at Northland
06/01/20 H.C. Wainwright
Menlo Therapeutics price target raised to $3.50 from $2.50 at H.C. Wainwright
05/29/20 Cantor Fitzgerald
Menlo set up for 'successful' Q4 launch of Zilxi, says Cantor Fitzgerald
05/21/20 Northland
Menlo Therapeutics initiated with an Outperform at Northland
MNLO Menlo Therapeutics
$2.37 /

-0.005 (-0.21%)

MNLO Menlo Therapeutics
$2.37 /

-0.005 (-0.21%)

MNLO Menlo Therapeutics
$2.37 /

-0.005 (-0.21%)

Recommendations
Menlo Therapeutics price target raised to $6 from $3.50 at Northland » 08:23
06/01/20
06/01
08:23
06/01/20
08:23
MNLO

Menlo Therapeutics

$2.37 /

-0.145 (-5.77%)

Northland analyst Tim…

Northland analyst Tim Chiang raised the firm's price target on Menlo Therapeutics to $6 from $3.50 and keeps an Outperform rating on the shares. The analyst believes Amzeeq and Zilxi will lead to "meaningful revenue growth" for the company. The recent approval of ZIlxi (adds a complementary product to Menlo's dermatology arsenal, Chiang tells investors in a research note.

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$2.37 /

-0.145 (-5.77%)

MNLO Menlo Therapeutics
$2.37 /

-0.145 (-5.77%)

06/01/20 H.C. Wainwright
Menlo Therapeutics price target raised to $3.50 from $2.50 at H.C. Wainwright
05/29/20 Cantor Fitzgerald
Menlo set up for 'successful' Q4 launch of Zilxi, says Cantor Fitzgerald
05/21/20 Northland
Menlo Therapeutics initiated with an Outperform at Northland
05/13/20 Barclays
Menlo Therapeutics price target raised to $3 from $2 at Barclays
MNLO Menlo Therapeutics
$2.37 /

-0.145 (-5.77%)

MNLO Menlo Therapeutics
$2.37 /

-0.145 (-5.77%)

MNLO Menlo Therapeutics
$2.37 /

-0.145 (-5.77%)

Recommendations
Menlo Therapeutics price target raised to $3.50 from $2.50 at H.C. Wainwright » 06:32
06/01/20
06/01
06:32
06/01/20
06:32
MNLO

Menlo Therapeutics

$2.37 /

-0.145 (-5.77%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Oren Livnat raised the firm's price target on Menlo Therapeutics to $3.50 from $2.50 and keeps a Buy rating on the shares. The analyst increased estimates for the company with Amzeeq volume already up 50% over the last four weeks as shutdowns start to lift. Amzeeq is bouncing back from COVID-19 faster than the analyst expected.

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$2.37 /

-0.145 (-5.77%)

MNLO Menlo Therapeutics
$2.37 /

-0.145 (-5.77%)

05/29/20 Cantor Fitzgerald
Menlo set up for 'successful' Q4 launch of Zilxi, says Cantor Fitzgerald
05/21/20 Northland
Menlo Therapeutics initiated with an Outperform at Northland
05/13/20 Barclays
Menlo Therapeutics price target raised to $3 from $2 at Barclays
05/12/20 H.C. Wainwright
Menlo Therapeutics price target raised to $2.50 from $2 at H.C. Wainwright
MNLO Menlo Therapeutics
$2.37 /

-0.145 (-5.77%)

MNLO Menlo Therapeutics
$2.37 /

-0.145 (-5.77%)

MNLO Menlo Therapeutics
$2.37 /

-0.145 (-5.77%)

Recommendations
Menlo set up for 'successful' Q4 launch of Zilxi, says Cantor Fitzgerald » 12:26
05/29/20
05/29
12:26
05/29/20
12:26
MNLO

Menlo Therapeutics

$2.55 /

+0.035 (+1.39%)

After Menlo Therapeutics…

After Menlo Therapeutics announced that Zilxi has received FDA approval for the treatment of inflammatory lesions of rosacea, Cantor Fitzgerald analyst Louise Chen said she views the approval positively and believes it sets up the company for a potential "successful" launch of its second FDA approved product in the fourth quarter of this year. Chen, who continues to believe that the peak sales potential for Menlo's products and pipeline are being "underappreciated," keeps an Overweight rating and $15 price target on the shares.

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$2.55 /

+0.035 (+1.39%)

MNLO Menlo Therapeutics
$2.55 /

+0.035 (+1.39%)

05/21/20 Northland
Menlo Therapeutics initiated with an Outperform at Northland
05/13/20 Barclays
Menlo Therapeutics price target raised to $3 from $2 at Barclays
05/12/20 H.C. Wainwright
Menlo Therapeutics price target raised to $2.50 from $2 at H.C. Wainwright
04/07/20 Barclays
Menlo Therapeutics price target lowered to $2 from $8 at Barclays
MNLO Menlo Therapeutics
$2.55 /

+0.035 (+1.39%)

MNLO Menlo Therapeutics
$2.55 /

+0.035 (+1.39%)

MNLO Menlo Therapeutics
$2.55 /

+0.035 (+1.39%)

Hot Stocks
Menlo Therapeutics receives FDA approval of ZILXI topical foam » 11:43
05/29/20
05/29
11:43
05/29/20
11:43
MNLO

Menlo Therapeutics

$2.58 /

+0.065 (+2.58%)

Menlo Therapeutics…

Menlo Therapeutics announced that the U.S. Food and Drug Administration has approved ZILXI topical foam, 1.5%, for the treatment of inflammatory lesions of rosacea in adults. ZILXI, developed as FMX103 by Menlo's wholly-owned subsidiary Foamix Pharmaceuticals, is the first minocycline product of any kind to be approved by the FDA for use in rosacea. Rosacea is a diverse skin condition that most commonly presents with symptoms such as deep facial redness, spider veins and acne-like inflammatory lesions. Minocycline is one of several broad-spectrum antibiotics known as tetracyclines with anti-inflammatory properties; their use in some patients is limited due to systemic side effects when taken orally. In ZILXI, Menlo has once more leveraged its proprietary Molecule Stabilizing Technology platform to effectively deliver minocycline in a foam-based vehicle. The FDA approval of ZILXI is primarily supported by data from two clinical trials in 1,522 patients 18 years of age and older. In each 12-week multicenter, randomized, double-blind, vehicle-controlled trial, subjects with inflammatory lesions of rosacea were treated once daily with ZILXI or vehicle. No other topical or systemic medication affecting the course of inflammatory lesions of rosacea was permitted for use during these trials. The co-primary efficacy endpoints were the absolute change from baseline in inflammatory lesion counts at Week 12 and the proportion of subjects with treatment success at Week 12 defined as an IGA score of 0 or 1, and at least a two-grade improvement from baseline at Week 12. ZILXI met both co-primary endpoints in each clinical trial, demonstrating statistically significant improvements in inflammatory lesion count and Investigator Global Assessment treatment success. No treatment-related serious adverse events were reported. The most common adverse reaction reported by greater than or equal to1% of subjects treated with ZILXI and more frequently than in subjects treated with vehicle was diarrhea, respectively. Menlo anticipates having ZILXI available for prescribing by 4th quarter of this year.

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$2.58 /

+0.065 (+2.58%)

MNLO Menlo Therapeutics
$2.58 /

+0.065 (+2.58%)

05/21/20 Northland
Menlo Therapeutics initiated with an Outperform at Northland
05/13/20 Barclays
Menlo Therapeutics price target raised to $3 from $2 at Barclays
05/12/20 H.C. Wainwright
Menlo Therapeutics price target raised to $2.50 from $2 at H.C. Wainwright
04/07/20 Barclays
Menlo Therapeutics price target lowered to $2 from $8 at Barclays
MNLO Menlo Therapeutics
$2.58 /

+0.065 (+2.58%)

MNLO Menlo Therapeutics
$2.58 /

+0.065 (+2.58%)

MNLO Menlo Therapeutics
$2.58 /

+0.065 (+2.58%)

Hot Stocks
Menlo Therapeutics announces covered status for AMZEEQ topical foam » 08:26
05/27/20
05/27
08:26
05/27/20
08:26
MNLO

Menlo Therapeutics

$2.40 /

+0.17 (+7.62%)

Menlo Therapeutics…

Menlo Therapeutics announced that its novel AMZEEQ topical foam, 4%, for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older, has been added to the prescription drug formulary of one of the largest payors in the U.S. AMZEEQ was approved by the U.S. Food and Drug Administration in October 2019. Minocycline, a broad-spectrum antibiotic known for its efficacy in treating moderate to severe acne, has not previously been available as a topical treatment due to its instability in traditional topical formulations. In AMZEEQ, Foamix has leveraged its proprietary Molecule Stabilizing Technology platform to deliver minocycline in a foam-based vehicle that maintains the stability of the active ingredient while delivering it directly on the skin.

ShowHide Related Items >><<
MNLO Menlo Therapeutics
$2.40 /

+0.17 (+7.62%)

MNLO Menlo Therapeutics
$2.40 /

+0.17 (+7.62%)

05/21/20 Northland
Menlo Therapeutics initiated with an Outperform at Northland
05/13/20 Barclays
Menlo Therapeutics price target raised to $3 from $2 at Barclays
05/12/20 H.C. Wainwright
Menlo Therapeutics price target raised to $2.50 from $2 at H.C. Wainwright
04/07/20 Barclays
Menlo Therapeutics price target lowered to $2 from $8 at Barclays
MNLO Menlo Therapeutics
$2.40 /

+0.17 (+7.62%)

MNLO Menlo Therapeutics
$2.40 /

+0.17 (+7.62%)

MNLO Menlo Therapeutics
$2.40 /

+0.17 (+7.62%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.